[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vanda Pharmaceuticals\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":426},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,47,72,96,125,152,180,199,226,251,273,306,332,354,376,398],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100609976","phase-3-study-to-evaluate-the-efficacy-and-safety-of-vqw-765-for-the-on-demand-treatment-of-social-anxiety-disorder-100609976",false,"NCT07221578","Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Acute Anxiety in Patients With Social Anxiety Disorder","Inclusion Criteria:\n\n1. Ability and willingness to provide written informed consent.\n2. Male and female subjects aged 18-65 years, inclusive.\n3. Current diagnosis of social anxiety disorder.\n4. Liebowitz Social Anxiety Scale total score ≥60.\n5. Public Speaking Anxiety Scale total score ≥60.\n6. Hamilton Depression Rating Scale score ≤18.\n\nExclusion Criteria:\n\n1. Suicide attempts and\u002For suicidal ideation in the past 2 years or currently at risk of suicide in the opinion of the investigator.\n2. History of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders, obsessive-compulsive disorder, or autism spectrum disorder.\n3. Posttraumatic stress disorder or an eating disorder in the past 6 months.\n4. Substance or alcohol use disorder in the past 6 months or positive in drug\u002Falcohol screening.\n5. Psychotherapy in the past 6 months.\n6. Psychotropic medication in the past 2 months.\n7. Current or planned pregnancy or nursing during the trial period.\n8. Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, or interference with study objectives.","ALL","18 Years","65 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.",[27],"Social Anxiety Disorder (SAD)",[29,30,31,32,33],"Social Anxiety Disorder","Social Phobia","SAD","Public Speaking Anxiety","Performance Anxiety","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2025-09-22",{"date":42,"type":21},"2027-04",{"name":44,"class":45},"Vanda Pharmaceuticals","INDUSTRY",31,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100620776","phase-3-open-label-study-to-investigate-the-safety-and-efficacy-of-ponesimod-in-moderate-to-severe-chronic-plaque-psoriasis-100620776","NCT07362017","Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis","Inclusion Criteria:\n\n* Male and female subjects aged 18-65 years, inclusive\n* BMI \\>18 and \\\u003C40\n* Minimum affected BSA of 10%\n* PASI score ≥ 12\n* PGA ≥ 3\n* Diagnosed with moderate-to-severe plaque psoriasis\n\nExclusion Criteria:\n\n* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis\n* History of an allergic reaction or known and\u002For significant sensitivity to study drug",{"count":55,"type":21},300,[24],"An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis",[59],"Moderate-to-severe Chronic Plaque Psoriasis",[61,62],"psoriasis","Moderate-to-severe chronic plaque psoriasis","2026-06-10",{"date":65,"type":38},"2026-06-11",{"date":67,"type":38},"2026-02-17",{"date":69,"type":21},"2028-12",{"name":44,"class":45},4,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100589396","phase-3-evaluating-the-effects-of-tasimelteon-vs-placebo-in-treating-pediatric-insomnia-100589396","NCT06953869","Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia","A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent of the participant or legal guardian (and assent as required).\n* Confirmed clinical diagnosis of insomnia disorder\n* Males and Females between 2 and 17 years, inclusive.\n* The sleep disturbance must not be a result of another medication.\n\nExclusion Criteria:\n\n* Inability to dose daily with tasimelteon or previous intolerance to tasimelteon.\n* Indication of impaired liver function.\n* Pregnant or lactating females.\n* A positive test for drugs of abuse.","2 Years","17 Years",{"count":82,"type":21},420,[24],"This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.",[86],"Insomnia Disorder","2026-06-03",{"date":89,"type":38},"2026-06-05",{"date":91,"type":38},"2025-04-21",{"date":93,"type":21},"2028-01",{"name":44,"class":45},35,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100627269","phase-3-a-study-to-evaluate-tradipitant-on-treating-nausea-and-vomiting-induced-by-glp-1r-agonist-use-100627269","NCT07446439","A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers","Inclusion Criteria:\n\n* Body Mass Index ≥ 25 and \\\u003C 40 kg\u002Fm\\^2\n* No serious medical problems or chronic diseases, specifically no type I or type II diabetes\n\nExclusion Criteria:\n\n* Another disorder that contributes to gastrointestinal symptoms\n* History of intolerance and\u002For hypersensitivity to NK-1 receptor antagonists\n* History of intolerance and\u002For hypersensitivity to GLP-1 receptor agonists\n* Exposure to any investigational medication within the past 60 days",true,{"count":105,"type":21},280,[24],"The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.",[109,110],"Nausea and Vomiting","Obesity",[112,113,114,115],"GLP-1R agonist","Semaglutide","Nausea","Vomiting","2026-04-14",{"date":118,"type":38},"2026-04-20",{"date":120,"type":38},"2026-03-27",{"date":122,"type":21},"2026-12-01",{"name":44,"class":45},10,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},"100350139","phase-1-tolerability-study-of-trichostatin-a-in-subjects-with-relapsed-or-refractory-hematologic-malignancies-100350139","NCT03838926","Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n* Subject is ≥ 18 years at the time of signing informed consent;\n* Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;\n* Presence of measurable or evaluable disease;\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;\n* Contraceptives or other approved avoidance of pregnancy measures\n\nExclusion Criteria:\n\n* Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;\n* Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);\n* Undergone major surgery ≤ 2 weeks prior to starting study drug;\n* Evidence of mucosal or internal bleeding;\n* Impaired cardiac function or conduction defect;\n* Concurrent severe and\u002For uncontrolled medical conditions",{"count":132,"type":21},42,[134],"PHASE1","The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.",[137],"Relapsed or Refractory Hematologic Malignancies",[139,140,141,142],"Hematologic","Malignancies","Cancer","Blood","2026-03-12",{"date":145,"type":38},"2026-03-16",{"date":147,"type":38},"2018-09-27",{"date":149,"type":21},"2027-12",{"name":44,"class":45},11,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100599874","phase-2-evaluation-of-efficacy-and-safety-of-iloperidone-for-the-treatment-of-participants-with-uncontrolled-hypertension-100599874","NCT07090161","Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","Inclusion Criteria:\n\n* SiSBP \\>\u002F= 130 mmHg despite \\>8 weeks treatment w\u002F 1 or more antihypertensive therapies\n\nExclusion Criteria:\n\n* Confirmed Grade 3\u002Fsevere hypertension (SiSBP \\>\u002F= 180 mmHg, SiDBP \\>\u002F= 120 mmHg), unstable cardiac disease, renal insufficiency",{"count":160,"type":21},240,[162],"PHASE2","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension",[165,166],"Hypertension","Uncontrolled Hypertension",[168,169,170],"iloperidone","hypertension","uncontrolled hypertension","2026-02-25",{"date":173,"type":38},"2026-02-27",{"date":175,"type":38},"2025-09-15",{"date":177,"type":21},"2026-11",{"name":44,"class":45},28,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100579880","phase-3-evaluation-of-efficacy-and-safety-of-milsaperidone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-100579880","NCT06830044","Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder","A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","Inclusion Criteria:\n\n* Male or female patient 18 to 65 years of age, inclusive;\n* Meets DSM-5-TR criteria for MDD\n* Currently having an inadequate response to antidepressant therapy as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ)\n\nExclusion Criteria:\n\n* Within the patients lifetime, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD\n* Within 6 months of Screening, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD\n* Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment",{"count":20,"type":21},[24],"The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder",[191],"Major Depressive Disorder (MDD)",{"date":173,"type":38},{"date":194,"type":38},"2025-03-03",{"date":196,"type":21},"2028-03",{"name":44,"class":45},38,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":225},"100590019","phase-3-randomized-withdrawal-study-in-patients-with-schizophrenia-100590019","NCT06961968","Randomized Withdrawal Study in Patients With Schizophrenia","A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection","Inclusion Criteria:\n\n* Males or females 18 to 65 years of age (inclusive)\n* Diagnosed with schizophrenia per DSM-5 criteria\n* In need of ongoing psychiatric treatment\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months",{"count":207,"type":21},400,[24],"The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.",[211],"Schizophrenia",[211,213,214,215,216],"Antipsychotic Agents","Iloperidone","Long-Acting Injection","Randomized Withdrawal","2026-01-09",{"date":219,"type":38},"2026-01-12",{"date":221,"type":38},"2025-05-14",{"date":223,"type":21},"2027-11",{"name":44,"class":45},22,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":250},"100412617","phase-3-evaluating-the-effects-of-tasimelteon-vs-placebo-in-delayed-sleep-wake-phase-disorder-dswpd-100412617","NCT04652882","Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)","A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Participants With Delayed Sleep-Wake Phase Disorder (DSWPD)","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent.\n* A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).\n* Men or women between 18 - 75 years, inclusive.\n* Body Mass Index (BMI) of ≥ 18 and ≤ 35 kg\u002Fm\\^2.\n\nExclusion Criteria:\n\n* Exacerbation of an existing psychiatric condition that requires change in treatment or intervention in the past 3 months.\n* Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.\n* Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.\n* A positive test for substances of abuse.\n* Current tobacco user.","75 Years",{"count":235,"type":21},70,[24],"This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.",[239,240,241],"Sleep Wake Disorders","Sleep Disorders, Circadian Rhythm","Chronobiology Disorders","2025-11-24",{"date":244,"type":38},"2025-12-02",{"date":246,"type":38},"2020-12-09",{"date":248,"type":21},"2026-06",{"name":44,"class":45},17,{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100606707","phase-2-an-eight-week-study-to-evaluate-the-safety-and-efficacy-of-vsj-110-compared-to-placebo-in-the-treatment-of-dry-eye-100606707","NCT07179055","An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye","An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye","Inclusion Criteria:\n\n* Be at least 18 years of age of either gender and any race.\n* Provide written informed consent and sign the HIPAA form.\n* Be willing and able to follow all instructions and attend all study visits.\n\nExclusion Criteria:\n\n* Use of any of the disallowed medications during the washout and study period.",{"count":259,"type":21},160,[162],"The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.",[263],"Dry Eye","2025-09-10",{"date":266,"type":38},"2025-09-17",{"date":268,"type":21},"2025-10",{"date":270,"type":21},"2026-09",{"name":44,"class":45},5,{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":280,"enrollmentInfo":4,"targetDuration":4,"studyType":281,"phases":4,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":300,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":304,"locationsCount":305},"100398963","single-patient-expanded-access-protocol-for-tradipitant-in-a-single-patient-with-gastroparesis-100398963","NCT04474990","Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","VP-VLY-686-3303: Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","Inclusion Criteria:\n\n* Identified subject who requested expanded access\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Patient does not qualify for or does not have access to other clinical trials with tradipitant;\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits;\n* Exposure to any investigational medication in the past 60 days other than tradipitant\n* Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year\n* Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit ratio to treatment;","70 Years","EXPANDED_ACCESS","Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant",[284,285],"Gastroparesis","Diabetic Gastroparesis",[287,288,289,290,291,292,293,294,295,296,297,298,299],"gastroparesis","idiopathic","diabetic","tradipitant","nausea","vomiting","stomach","motility","functional","NK-1 antagonist","neurokinin 1 receptor","substance p","expanded access","AVAILABLE","2025-08-18",{"date":303,"type":38},"2025-08-24",{"name":44,"class":45},15,{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":313,"maxAge":80,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":318,"conditions":319,"keywords":321,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},"100489090","phase-4-safety-and-tolerability-of-open-labeled-iloperidone-in-adolescents-100489090","NCT05648591","Safety and Tolerability of Open-Labeled Iloperidone in Adolescents","Open-label Safety Study of a 1-year 8 to 24 mg\u002FDay Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder","Inclusion Criteria:\n\n* Patient is willing and able to provide assent and willing to complete all aspects of the study\n* Patient's parent or legal guardian willing and able to provide consent\n* Male or female patients 12 through 17 years of age (inclusive)\n* Clinical diagnosis of either schizophrenia or bipolar I disorder\n\nExclusion Criteria:\n\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer\n* A positive test for drugs of abuse","12 Years",{"count":315,"type":21},100,[317],"PHASE4","To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.",[211,320],"Bipolar I Disorder",[322],"fanapt","2025-02-27",{"date":325,"type":38},"2025-03-04",{"date":327,"type":38},"2023-05-24",{"date":329,"type":21},"2026-11-30",{"name":44,"class":45},9,{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":280,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},"100580381","phase-3-open-label-safety-study-of-tradipitant-in-idiopathic-and-diabetic-gastroparesis-100580381","NCT06836557","Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis","A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis","Inclusion Criteria:\n\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Body Mass Index (BMI) of ≥18 and ≤40 kg\u002Fm2\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits\n* Pregnancy or nursing\n* Evidence of uncontrolled blood glucose (including HbA1C \\>11% at screening or metabolic crisis in past 60 days)",{"count":315,"type":21},[24],"This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.",[343,285,284],"Idiopathic Gastroparesis",[287,288,289,290,291,292,293,294,295,296,297,298],"2025-02-14",{"date":347,"type":38},"2025-02-20",{"date":349,"type":38},"2024-01-09",{"date":351,"type":21},"2025-12",{"name":44,"class":45},3,{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":375},"100569988","phase-3-evaluating-the-effects-of-tasimelteon-vs-placebo-in-delayed-sleep-wake-phase-disorder-dswpd-and-the-cry111-variant-100569988","NCT06701396","Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","A Double-Blind, Randomized, Two-Period Crossover Study to Evaluate the Effects of Tasimelteon Vs. Placebo in Subjects with Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent.\n* A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).\n* Carrier of CRY1Δ11 variant.\n* Men or women between 18 - 75 years, inclusive.\n* Body Mass Index (BMI) of ≥ 18 and ≤ 40 kg\u002Fm\\^2.\n\nExclusion Criteria:\n\n* Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.\n* Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.\n* A positive test for substances of abuse.\n* Current tobacco user.",{"count":362,"type":21},60,[24],"This is a double-blind, randomized, two-period crossover study to evaluate the efficacy and safety of a single oral dose of tasimelteon and matching placebo in male and female subjects with DSWPD and the CRY1Δ11 variant.",[239,240,241,366],"Gene Mutations and Other Alterations Nec","2024-11-19",{"date":369,"type":38},"2024-11-22",{"date":371,"type":38},"2024-10-08",{"date":373,"type":21},"2025-06-30",{"name":44,"class":45},1,{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":383,"maxAge":18,"enrollmentInfo":384,"targetDuration":4,"studyType":386,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":375},"100297645","development-of-clinical-database-of-individuals-with-smith-magenis-syndrome-and-sleep-disturbances-100297645","NCT03154697","Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances","Development of Clinical Database of Individuals With Smith-Magenis Syndrome","Inclusion Criteria:\n\n* Parent or legal guardian of individual with Smith-Magenis Syndrome\n\nExclusion Criteria:\n\n* Not legal guardian of individual with SMS","3 Years",{"count":385,"type":21},1000,"OBSERVATIONAL","This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.",[389],"Sleep Disturbances in Smith-Magenis Syndrome","2024-03-19",{"date":392,"type":38},"2024-03-20",{"date":394,"type":38},"2016-01",{"date":396,"type":21},"2030-12",{"name":44,"class":45},{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":386,"phases":4,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":375},"100147817","patient-registry-of-blind-subjects-with-sleep-related-problems-100147817","NCT01195558","Patient Registry of Blind Subjects With Sleep-related Problems","Development of a Patient Registry of Blind Subjects With Sleep-related Problems","Inclusion Criteria:\n\n1. Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria.\n2. Subjects must be blind.\n3. Subjects must have some self-described problem with sleep or daytime sleepiness.",{"count":406,"type":21},10000,"Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.",[409],"Sleep-wake Disorder in Blind Individuals",[411,412,413,414,415,416,417],"Non-24","N24HSWD","Blindness","Sleep","Wake","Circadian Rhythm","Nap","2020-06-22",{"date":420,"type":38},"2020-06-24",{"date":422,"type":4},"2010-04",{"date":424,"type":21},"2030-04",{"name":44,"class":45},""]